---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description. Covers Product description and Place of product in therapy. 205 evidence topics quoted from 82 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Investigational status and development phase

> “announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for onvuzosiran, an investigational small interfering RNA (siRNA) therapeutic candidate, for prophylaxis to prevent attacks of hereditary angioedema (HAE).”

Source: [ADARx Pharmaceuticals Fast Track designation announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-receives-fda-fast-track-designation-for-onvuzosiran-for-the-treatment-of-hae/)

> “Onvuzosiran is currently being evaluated in the Phase 3 STOP-HAE clinical trial ( NCT06960213 ).”

Source: [ADARx Pharmaceuticals third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458321/adrx-ex99_1.htm)

> “have no products approved for commercial sale”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.1-2"></a>

##### Regulatory status: Submission planned; NDA submission anticipated in 2028

> “STOP-HAE enrollment is ongoing, with topline data expected by the end of 2027. If STOP-HAE data are positive, we anticipate a potential New Drug Application (NDA) submission in 2028.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.1-3"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-4"></a>

##### Anticipated milestones: phase 3 topline data and study completion dates

> “Onvuzosiran (PKK): Phase 3 STOP-HAE topline data by year-end 2027”

Source: [ADARx Pharmaceuticals third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458321/adrx-ex99_1.htm)

> “STOP-HAE topline data expected by YE2027”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

> “Primary Completion (Estimated) 2027-11-30”
> “Study Completion (Estimated) 2027-12-31”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

> “Primary Completion (Estimated) 2030-06-30”

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="topic-2.1.1-5"></a>

##### Development history: phase 1/2 study start and status

> “Study Start (Actual) 2022-12-14”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

> “today announced the dosing of the first cohort in a Phase 1 clinical study of ADX-324 for the treatment of hereditary angioedema (HAE).”

Source: [ADARx Pharmaceuticals (2023)](https://www.adarx.com/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324/)

> “In January 2024, we initiated our Phase 2a clinical trial of SC doses of onvuzosiran in patients with HAE.”
> “While patients continue to be dosed, given the reduction in HAE attack rate observed as of the August 19, 2026 data cutoff date, we believe sufficient safety, PK data and PD data have been collected to assess the primary and secondary objectives.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.1-6"></a>

##### Development history: phase 3 and extension study start

> “In August 2025, we initiated our Phase 3 STOP-HAE clinical trial.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

> “October 22, 2025”
> “today announced that the first patient has been dosed in its Phase 3 STOP-HAE clinical trial evaluating ADX-324 in patients with hereditary angioedema (HAE).”

Source: [ADARx Pharmaceuticals (2025)](https://www.adarx.com/adarx-pharmaceuticals-announces-first-patient-dosed-in-phase-3-stop-hae-clinical-trial-and-orphan-drug-designation-for-adx-324-a-long-acting-sirna-in-development-for-the-prophylactic-treatment-of-her/)

> “Study Start (Actual) 2026-04-02”

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="topic-2.1.1-7"></a>

##### FDA orphan drug designation

> “the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ADX-324 for the treatment of patients with HAE”

Source: [ADARx Pharmaceuticals (2025)](https://www.adarx.com/adarx-pharmaceuticals-announces-first-patient-dosed-in-phase-3-stop-hae-clinical-trial-and-orphan-drug-designation-for-adx-324-a-long-acting-sirna-in-development-for-the-prophylactic-treatment-of-her/)

> “In October 2025, the FDA granted orphan drug designation to onvuzosiran for the treatment of patients with HAE.”

Source: [ADARx Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458444/adrx-20260930.htm)

<a id="topic-2.1.1-8"></a>

##### FDA Fast Track designation

> “In August 2026, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to onvuzosiran for prophylaxis to prevent attacks of hereditary angioedema (HAE).”

Source: [ADARx Pharmaceuticals third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458321/adrx-ex99_1.htm)

> “The benefits of Fast Track designation include opportunities for frequent meetings with the FDA to discuss trial design, development plans and data needed to support drug approval, as well as the ability to submit a New Drug Application (NDA) on a rolling basis, and eligibility for priority review, if relevant criteria are met.”

Source: [ADARx Pharmaceuticals Fast Track designation announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-receives-fda-fast-track-designation-for-onvuzosiran-for-the-treatment-of-hae/)

<a id="topic-2.1.1-9"></a>

##### FDA feedback on the phase 3 design

> “Positive feedback from FDA to move forward with Phase 3 STOP-HAE study.”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

> “Per feedback from the FDA, HAE attacks before Day 22 will be excluded from primary endpoint analysis, consistent with the siRNA proposed mechanism of action.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.1-10"></a>

##### Regulatory designations outside the United States

No evidence found.

<a id="topic-2.1.1-11"></a>

##### Patent protection

> “We own one issued U.S. utility patent, four pending U.S. utility patent applications, and 20 pending patent applications in Australia, Brazil, Canada, Chile, China, Colombia, Europe, Hong Kong, India, Israel, Japan, Korea, Malaysia, Mexico, New Zealand, Peru, Singapore, South Africa, and Taiwan that contain claims directed to the onvuzosiran composition of matter and to methods of treating diseases of interest using onvuzosiran.”
> “Patents issuing from these applications, if any, are expected to expire in 2042 and 2044, respectively, excluding any additional term for patent term adjustment or patent term extension.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: ADARx Pharmaceuticals

> “ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for onvuzosiran”

Source: [ADARx Pharmaceuticals Fast Track designation announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-receives-fda-fast-track-designation-for-onvuzosiran-for-the-treatment-of-hae/)

<a id="topic-2.1.2.1-2"></a>

###### Ownership

> “We currently have five wholly-owned therapeutic candidates in clinical and preclinical development.”
> “Onvuzosiran, our most advanced clinical program, targets prekallikrein (PKK) for the prevention of hereditary angioedema (HAE) attacks.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.1-3"></a>

###### Nonproprietary name, development code, and therapeutic class

> “onvuzosiran (ADX-324), an investigational small interfering RNA (siRNA) therapeutic candidate being developed for the treatment of hereditary angioedema (HAE)”

Source: [ADARx Pharmaceuticals onvuzosiran data announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-presents-onvuzosiran-data-supporting-potential-for-sustained-attack-free-rates-with-reduced-treatment-burden-in-patients-with-hae/)

> “Onvuzosiran (ADX-324) is a small interfering RNA (siRNA) therapy consisting of short oligonucleotides”

Source: [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)

<a id="topic-2.1.2.1-4"></a>

###### Brand name

No evidence found.

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Investigational drug substance and placebo

> “Drug: ADX-324 siRNA duplex oligonucleotide”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-2.1.2.2-2"></a>

###### Phase 3 doses and injection volumes

| Arm | Quoted dose and volume |
| --- | --- |
| Onvuzosiran every 6 months | “ADX-324 300 mg Q6M (1.5ml)” |
| Onvuzosiran every 3 months | “ADX-324 240 mg Q3M (1.2ml)” |
| Placebo matched to the 6-month regimen | “Placebo (1.5 ml) n=15” |
| Placebo matched to the 3-month regimen | “Placebo (1.2 ml) n=15” |

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-2.1.2.2-3"></a>

###### Injection volume

> “Onvuzosiran is given in a small volume subcutaneous injection”

Source: [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)

<a id="topic-2.1.2.2-4"></a>

###### Material safety data sheet

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### WHO International Nonproprietary Name functional class

> “prekallikrein synthesis reducer”

Source: [World Health Organization (2024)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf)

<a id="topic-2.1.2.4-2"></a>

###### AHFS classification

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Indication named in the FDA Fast Track designation

> “In August 2026, we received Fast Track designation for onvuzosiran for prophylaxis to prevent attacks of HAE from the FDA.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.5-2"></a>

###### Indication named in the FDA orphan drug designation

> “In October 2025, the FDA granted orphan drug designation to onvuzosiran for the treatment of patients with HAE.”

Source: [ADARx Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458444/adrx-20260930.htm)

<a id="topic-2.1.2.5-3"></a>

###### Investigational population in the phase 3 trial

> “We are conducting our randomized, double-blind, placebo-controlled Phase 3 STOP-HAE clinical trial designed to evaluate the efficacy and safety of onvuzosiran in 90 adults with Type I or Type II HAE.”

Source: [ADARx Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458444/adrx-20260930.htm)

> “Age ≥18 years at the time of signing informed consent.”
> “Have a documented diagnosis of HAE-1/HAE-2 (Type I or II)”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Prekallikrein mRNA degradation in the liver

> “Onvuzosiran’s mechanism of action is designed to degrade PKK mRNA in the liver, thereby resulting in the reduction of plasma kallikrein levels by preventing the production of its proenzyme, PKK.”
> “Onvuzosiran is designed to reduce bradykinin by selectively silencing PKK mRNA for degradation in the liver and prevent protein synthesis.”
> “This reduces circulating PKK protein levels and prevents activation of the bradykinin pathway that underlies HAE attacks”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.6.1-2"></a>

###### RNA interference: RISC-mediated cleavage of target mRNA

> “A protein complex known as RISC recognizes the siRNA duplex, and an endogenous nuclease, Argonaute 2 (Ago2), unravels the duplex, discards the passenger strand and retains the guide strand, forming the loaded RISC.”
> “Once the siRNA guide strand is hybridized to the target mRNA, the RISC cleaves the mRNA, leading to its degradation and preventing the translation of the mRNA into protein.”
> “Unlike ASOs, which employ a different mechanism as a single strand construct, siRNAs remain bound to the RISC, silencing multiple mRNA copies, resulting in long-term PD effects.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.6.1-3"></a>

###### Congress reports: prekallikrein mRNA cleavage and bradykinin generation

> “ADX-324 is an investigational siRNA therapy designed to inhibit prekallikrein (PKK) generation at the mRNA level and reduce the production of plasma PKK, thereby averting bradykinin generation and potentially preventing HAE attacks.”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

> “ADX-324 is an investigational siRNA that cleaves prekallikrein (PKK) mRNA, thereby preventing HAE attacks.”

Source: [Murai et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.095)

> “ADX-324 is an investigational siRNA that strongly inhibits the production of prekallikrein (PKK), reducing bradykinin generation, preventing HAE attacks.”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

> “ADX-324 is a siRNA duplex oligonucleotide that inhibits prekallikrein (PKK), offering the possibility of prevention of HAE attacks by a single subcutaneous injection every six months.”

Source: [Smith et al. (2023)](https://www.annallergy.org/article/S1081-1206%2823%2900702-0/fulltext)

<a id="topic-2.1.2.6.1-4"></a>

###### Molecular structure and hepatic targeting

> “prekallikrein synthesis reducer”

Source: [World Health Organization (2024)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf)

> “GalNAc3-conjugated siRNA targeting hepatic prekallikrein mRNA”
> “It selectively targets hepatic prekallikrein mRNA to reduce prekallikrein production.”

Source: [Uminski et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12618362/)

<a id="topic-2.1.2.6.1-5"></a>

###### Distinction from gene therapy

> “It’s important to note that ADX-324 is not a gene-therapy and does not change a person’s DNA.”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="topic-2.1.2.6.1-6"></a>

###### Hepatic targeting for novel prophylactic therapies: review

> “This report reviews currently available data on hepatic-focused interventions for HAE that have advanced into human trials.”

Source: [Riedl et al. (2024a)](https://pure.amsterdamumc.nl/en/publications/clinical-progress-in-hepatic-targeting-for-novel-prophylactic-the)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Phase 1 interim: nadir prekallikrein by weight-based dose

> “Mean nadir PKK levels were 39% (n=6), 14% (n=6), and 20% (n=5) of baseline following single doses of 0.4, 1.0, and 2.0 mg/kg, respectively.”
> “Cohort 2 PKK mean level remains 21% 99 days post-dose.”

Source: [Smith et al. (2023)](https://www.annallergy.org/article/S1081-1206%2823%2900702-0/fulltext)

<a id="topic-2.1.2.6.2-2"></a>

###### Phase 1: 6 mg/kg single dose

> “we observed at the 6 mg/kg dose level that a single injection reduced circulating PKK/KK levels by a mean of 94% (88% to 97%, median 96%) at nadir and maintained 84% mean suppression (78% to 92%, median 82%) at 6 months.”
> “Three of the four participants at this dose level reached below LLOQ for PKK/KK levels at nadir.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.6.2-3"></a>

###### Phase 1: 300 mg (plus or minus 25 mg) single fixed dose, prospectus

> “When analyzed by total fixed dose, we observed in healthy volunteers that following a single 300 mg +/- 25 mg achieved comparable performance, exceeding 90% mean reduction (84% to 96%, median 95%) at nadir with at least 80% mean suppression (65% to 90%, median 83%) sustained through the six-month timepoint (Day 169, as defined in our Phase 3 STOP-HAE trial)”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.6.2-4"></a>

###### Phase 1: 300 mg single dose, congress reports

> “In Phase 1, a single SC injection of ADX-324 at 300 mg (±25 mg) achieved a mean PKK-KK reduction from baseline of over 90% at nadir, with >80% reduction maintained through Day 169.”
> “In HV, the 300 mg dose, not a lower one, achieved a 93% mean PKK-KK reduction at nadir and an 80% mean reduction at 6 month”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

> “A single SC injection of ADX-324 of 300 mg (± 25 mg) achieved a mean (SEM) PKK-KK reduction from baseline of > 90% at nadir, and > 80% reduction % maintained out to Day 169 (Week 25)”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

> “In Phase 1, a single SC dose of 300 mg reduced plasma kallikrein levels to over 90% at nadir, with maintenance of 80% reduction through Week 25.”

Source: [Cancian et al. (2026a)](https://www.adarx.com/wp-content/uploads/2026/06/EAACI-2026_Cancian-et-al-abstract-vF.pdf)

<a id="topic-2.1.2.6.2-5"></a>

###### Phase 1: 300 mg single dose, sponsor press release

> “The 300 mg dose showed a 93% reduction at the lowest point, with 80% reduction maintained through Day 169.”

Source: [ADARx Pharmaceuticals onvuzosiran data announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-presents-onvuzosiran-data-supporting-potential-for-sustained-attack-free-rates-with-reduced-treatment-burden-in-patients-with-hae/)

<a id="topic-2.1.2.6.2-6"></a>

###### Phase 1: 300 mg dose cohort as attributed in the November 2026 corporate presentation

> “Phase 1 support: 94% mean (88-97%) reduction at nadir, 84% mean (78-92%) reduction at 6mo at 300 mg +/-25 mg Q6M”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

<a id="topic-2.1.2.6.2-7"></a>

###### Onset: lag to full prekallikrein inhibition

> “One known feature of siRNA therapeutic candidates such as onvuzosiran is lag time of about 22 days between initial treatment and full inhibition.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.6.2-8"></a>

###### Phase 2a: prekallikrein reduction in participants with HAE compared with healthy volunteers

> “The PD results showed similar PKK inhibition between healthy volunteers in the Phase 1 clinical trial and HAE patients.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

> “In Phase 2, one patient received 122.5 mg and two patients received 245 mg.”
> “Their PKK-KK reductions mirrored those observed in healthy subjects dosed with ADX-324 at similar levels, supporting the Phase 3 target >80% PKK-KK reduction throughout 6 months in HAE patients at the 300 mg dose.”

Source: [Murai et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.095)

> “In Phase 2, HAE patients experienced plasma kallikrein levels reductions comparable to those seen in Phase 1.”

Source: [Cancian et al. (2026a)](https://www.adarx.com/wp-content/uploads/2026/06/EAACI-2026_Cancian-et-al-abstract-vF.pdf)

<a id="topic-2.1.2.6.2-9"></a>

###### Phase 2a: prekallikrein suppression threshold associated with absence of attacks

> “We also correlated the episodes of attack with the PKK levels and found that no attacks occurred when the PKK suppression was >80%, suggesting that >80% suppression is potentially needed to achieve a maximal attack-free state.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

> “Notably, Phase 2 patients with >80% PKK-KK reductions experienced no HAE attacks, further supporting the potential of 300 mg Q6M to improve attack-free rates.”

Source: [Murai et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.095)

> “The patients’ data also supports that PKK-KK response can be used to predict HAE attacks and PKK-KK reductions > 70% are likely to prevent HAE attacks.”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

> “No attacks observed when PKK & KK reduction >80%”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

<a id="topic-2.1.2.6.2-10"></a>

###### Preclinical studies: serum prekallikrein after a single 4 mg/kg dose in nonhuman primates

> “Following a single 4 mg/kg SC dose of onvuzosiran to NHPs (n=2), serum PKK/KK levels were assessed over a 92-day period by enzyme-linked immunosorbent assay (ELISA) and compared to the baseline level prior to dosing (Figure 12).”
> “Administration of onvuzosiran led to a >80% reduction of serum PKK from Day 22 through Day 78, with a 94% reduction of serum PKK at nadir on Day 50.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.6.2-11"></a>

###### Preclinical studies: prekallikrein suppression at 200 mg/kg in nonhuman primates

> “NHP study shows deep suppression of prekallikrein with no safety concerns at supratherapeutic doses”

Source: [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)

> “Results from the high dose NHP study showed no adverse events, supporting the safety of 300 mg dose, and reduction of prekallikrein protein levels as well as prekallikrein activity.”

Source: [Riedl et al. (2026b)](https://www.annallergy.org/article/S1081-1206%2826%2900563-6/fulltext)

<a id="topic-2.1.2.6.2-12"></a>

###### Preclinical studies: projected dosing interval from nonhuman primate data

> “our pre-clinical studies in non-human primates have confirmed the likelihood for a bi-annual, and possibly annual, low volume subcutaneous dose regimen for ADX-324”

Source: [ADARx Pharmaceuticals (2023)](https://www.adarx.com/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324/)

<a id="topic-2.1.2.6.2-13"></a>

###### Nonclinical toxicology: nonhuman primates and rabbits

> “In safety pharmacology, repeat-dose toxicology, and genotoxicity studies in NHPs, we observed no adverse effects with onvuzosiran, and NOAELs were established at the highest doses tested (up to 200 mg/kg subacute and 96 mg/kg chronic).”
> “Reproductive and developmental studies in rabbits showed no drug-related effects on fertility or embryo-fetal development.”
> “We observed a 25-fold safety margin at the 300 mg clinical dose.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

> “Results from the high dose NHP study showed no adverse events, supporting the safety of 300 mg dose (5 mg/kg).”

Source: [Cancian et al. (2026a)](https://www.adarx.com/wp-content/uploads/2026/06/EAACI-2026_Cancian-et-al-abstract-vF.pdf)

<a id="topic-2.1.2.6.2-14"></a>

###### Nonclinical toxicology: off-target effects observed in rats

> “our determination that rat is not an appropriate species for the evaluation of the long-term safety of onvuzosiran may be incorrect, and the off-target effects and lack of pharmacologic activity that we observed in our preclinical rat studies may prove to be relevant to our ongoing and future onvuzosiran clinical trials.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Plasma exposure and half-life: phase 1 and phase 2

> “Dose-dependent ADX-324 exposure was observed, with plasma mean t½ ranging from 3.73 to 7.16 hours”
> “ADX-324 demonstrates dose-dependent PK and PD in both healthy volunteers (HV) and HAE patients”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-2.1.2.6.3-2"></a>

###### Short plasma circulation relative to pharmacodynamic duration

> “Very Short Circulatory Time Produces Long Durability”

Source: [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)

<a id="topic-2.1.2.6.3-3"></a>

###### Planned pharmacokinetic parameters: phase 1/2 registry record

> “To characterize the Pharmacokinetics of ADX-324 in HVs by measuring the Maximum observed concentration (Cmax)”
> “To characterize the Pharmacokinetics of ADX-324 in HVs by measuring the Total apparent body clearance (CL/F)”
> “To characterize the Pharmacokinetics of ADX-324 in HVs by measuring the Apparent volume of distribution (Vz/F)”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Pediatric patients: trial enrollment limited to adults

> “Age ≥18 years at the time of signing informed consent.”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-2.1.2.8-2"></a>

###### Older adults: phase 1 age range

> “Male and female adults 18 to 55 years old”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-2.1.2.8-3"></a>

###### Renal impairment: exclusion from trials

> “Any clinically significant renal disease”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

> “Estimated creatinine clearance <60 mL/min or serum creatinine > 1.5-fold upper limit of normal.”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-2.1.2.8-4"></a>

###### Hepatic impairment: exclusion from trials

> “Any clinically significant hepatic disease”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

> “History of liver disease, Gilbert's syndrome, or abnormal liver function test”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-2.1.2.8-5"></a>

###### Pregnancy and lactation: exclusion from the phase 1/2 study

> “Pregnancy, intent to become pregnant during the course of the study, or lactating women”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-2.1.2.8-6"></a>

###### Pregnancy and fertility: nonclinical reproductive studies

> “Reproductive and developmental studies in rabbits showed no drug-related effects on fertility or embryo-fetal development.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Onvuzosiran

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Onvuzosiran on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Investigational phase 3 regimens

> “Approximately 90 patients will be enrolled and randomized to receive either ADX-324 300 mg every 6 months, ADX-324 240 mg every 3 months, or placebo during the study.”

Source: [ADARx Pharmaceuticals (2025)](https://www.adarx.com/adarx-pharmaceuticals-announces-first-patient-dosed-in-phase-3-stop-hae-clinical-trial-and-orphan-drug-designation-for-adx-324-a-long-acting-sirna-in-development-for-the-prophylactic-treatment-of-her/)

<a id="topic-2.1.2.10.1-2"></a>

###### Blinded dosing schedule in the phase 3 trial

> “Participants will be randomly assigned to 1 of 3 treatment groups. 1) ADX-324 300mg on day 1 (D1) + Placebo on Week 13 (W13), 2) ADX-324 240mg D1 + ADX-324 240mg W13, 3) Placebo D1 + Placebo W13.”

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/stop-hae-a-phase-3-study-of-adx-324-in-hae/)

<a id="topic-2.1.2.10.1-3"></a>

###### Phase 2a doses and dose selection for phase 3

> “Phase 2a doses: 122.5 mg Q6M, or 245 mg Q6M; Phase 3 dose cohorts: 300 mg Q6M or 240 mg Q3M”
> “The attack-free interval seen with these subtherapeutic doses supported our choice of doses in our ongoing STOP-HAE Phase 3 trial.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

> “For HAE patients, 300 mg Q6M subcutaneous (SC) injection projected to maintain 80% (preferred) mean reduction target at 6-month.”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-2.1.2.10.1-4"></a>

###### Dosing in the phase 3 extension study

> “Participants who received ADX-324 in the core study will continue to receive the same dosing regimen as in the core study (ie, ADX-324 300 mg every 6 months [Q6M] in Group 1 or 240 mg every 3 months [Q3M] in Group 2).”
> “Participants who received placebo 1.5 mL in the core study will receive ADX-324 300 mg Q6M (Group 1) and those who received placebo 1.2 mL in the core study will receive 240 mg Q3M (Group 2).”
> “In order to maintain the blind in the core study, all participants will receive an injection Q3M; participants in the Q6M regimen will alternate between ADX-324 and placebo Q3M while participants in the Q3M group will receive ADX-324 Q3M as outlined.”

Source: [Health Research Authority (2026)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/extension-study-of-adx-324-in-hae/)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Route and dosing interval

> “We believe our durability results support the potential for once every six months (Q6M) and once every three months (Q3M) dosing via subcutaneous (SC) injection.”

Source: [ADARx Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458444/adrx-20260930.htm)

> “ADX-324 comes as subcutaneous injection which means it’s injected under the skin.”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="topic-2.1.2.10.2-2"></a>

###### Phase 3 visit schedule

> “After the start of study drug administration, participants will return to the hospital for 7 post-dose visits at 2- or 4-week intervals for effectiveness and safety tests for 6 months.”

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/stop-hae-a-phase-3-study-of-adx-324-in-hae/)

> “Screening, Day 1 (Dose 1), W3, W5, W9, W13 (Dose 2), W17, W21, W25 (EoS)”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Commercial infrastructure

> “We currently have no marketing and sales organization and have no experience as a company in commercializing products”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.11-2"></a>

###### Manufacturing and supply

> “We currently engage with third-party contract development manufacturing organizations (CDMOs) for the manufacture of our therapeutic candidates and we intend to continue to do so in the future.”
> “We rely on and expect to continue to engage third-party manufacturers for the production of both drug substance and finished drug product.”
> “We currently obtain our supplies from these manufacturers on a purchase order basis and do not have long-term supply arrangements in place.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.11-3"></a>

###### Continued investigational access after the phase 3 trial

> “All eligible participants in the main study will be enrolled on the extension study and administered ADX-324 for up to 3 years.”

Source: [Health Research Authority (2026)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/extension-study-of-adx-324-in-hae/)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### STOP-HAE: access to acute on-demand therapy

> “Able to use at least one acute therapy to treat HAE attacks (such as a plasma-derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

> “Access to acute medication(s) for attacks provided for all study participants”

Source: [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)

<a id="topic-2.1.2.12-2"></a>

###### STOP-HAE: washout of long-term prophylaxis

> “Have used any of the following for long-term prevention of HAE attacks: C1-INH agent (CINRYZE, HAEGARDA, RUCONEST) within 2 weeks prior to Screening.”
> “Berotralstat (ORLADEYO) within 3 weeks prior to Screening.”
> “Lanadelumab (TAKHZYRO) within 8 weeks prior to the Screening.”
> “Androgen use within 12 weeks prior to Screening.”
> “Received prior treatment with any RNA/DNA-based therapy for HAE or intolerant to any prior RNA/DNA-based therapy for any condition, excluding vaccines.”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

> “In this trial, participants undergo a washout of previous long term prophylaxis treatment and then enter a 4-week screening window where baseline HAE attack rate is measured”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.12-3"></a>

###### Phase 1/2 study, HAE cohort: acute therapy and prior prophylaxis

> “Participants must have access to, and the ability to use, acute medication(s) to treat angioedema attacks.”
> “Use of C1-INH products, androgens, antifibrinolytics or other small molecule medications for routine prophylaxis within four half-lives prior to screening”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-2.1.2.12-4"></a>

###### Phase 3 extension study: access to acute therapy

> “Have access to an acute therapy to treat HAE attacks (such as plasma derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)”

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Onvuzosiran on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Donidalorsen: same target, different oligonucleotide mechanism

> “The potential clinical benefit of targeting PKK mRNA is supported by Phase 3 data from donidalorsen, a GalNAc-conjugated ASO that also inhibits PKK mRNA.”
> “Onvuzosiran uses the same biological target as donidalorsen but achieves degradation through a more efficient biological mechanism using the cell’s own natural mRNA regulation system, thereby offering the potential for deeper and more durable PKK suppression.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

> “Donidalorsen is an ASO-GalNAc conjugate that causes ribonuclease H1 (RNase H1)-mediated degradation of PKK mRNA through binding to PKK mRNA, which results in reduced production of PKK protein.”

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="topic-2.1.2.14-2"></a>

###### Donidalorsen: plasma prekallikrein reduction in OASIS-HAE

> “The mean percentage change from baseline to Week 24 in trough plasma PKK concentrations indicated reductions of 73% and 47% following”
> “treatment with DAWNZERA 80 mg every 4 weeks and every 8 weeks, respectively, compared with a slight increase (2%) observed in the placebo group.”

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="topic-2.1.2.14-3"></a>

###### Donidalorsen: attack-free rate and dosing frequency as described by the sponsor of onvuzosiran

> “dosing every 4 to 8 weeks remains burdensome for patients and, with an attack-free rate in the Phase 3 study of only 35% (Q8W) to 53% (Q4W), it leaves room for significant improvement in the field.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.14-4"></a>

###### Donidalorsen: mean attack rate per four weeks in OASIS-HAE

| Treatment | Attack rate |
| --- | --- |
| Donidalorsen every four weeks | “0.44” |
| Donidalorsen every eight weeks | “1.02” |
| Placebo | “2.26” |

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="topic-2.1.2.14-5"></a>

###### Approved prophylactic agents: limitations described by the sponsor of onvuzosiran

> “These approved prophylactic therapies have provided HAE patients with treatment options but have significant limitations, particularly with respect to efficacy (attack-free rate and reduction in attack frequency), side effects and importantly, frequency of administration.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

> “Compared to currently approved prophylactic treatments, ADX-324 is expected to decrease PKK to a greater degree, offering the potential for greater and more durable control of kallikrein activity, which is expected to result in a higher proportion of patients remaining attack-free with a less frequent dosing regimen.”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-2.1.2.14-6"></a>

###### Onvuzosiran target product profile

> “Our target profile for onvuzosiran is to reach greater than 90% reduction in monthly attacks, with greater than 75% of patients achieving attack-free status, on Q3M or Q6M dosing schedule.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.14-7"></a>

###### Competing prekallikrein siRNA BW-20805: phase 1 in healthy volunteers

> “BW-20805 is a siRNA that inhibits prekallikrein (PKK), offering the possibility of prevention of Hereditary Angioedema (HAE) attacks with a significant, longer acting effect.”
> “The mean maximum reduction in PKK level from baseline after dosing were 75% (50 mg),87% (150 mg),94% (300 mg), and 95% (600mg).”
> “Those reductions were sustained, remaining greater than 55% (50 mg), 69% (150 mg) and 77% (300 mg) and 84% (600 mg) up to Week 24 post-dose.”
> “The most common study drug-related AEs were mild, transient injection site reactions.”

Source: [Wong et al. (2025)](https://www.annallergy.org/article/S1081-1206%2825%2900537-X/fulltext)

<a id="topic-2.1.2.14-8"></a>

###### Competing prekallikrein siRNA BW-20805: phase 2 in participants with HAE

> “As of the June 2026 data cut-off, 25 participants were randomized and dosed across three treatment groups: BW-20805: 600 mg every 24 weeks (Q24W), 300 mg Q24W, and 300 mg every 12 weeks (Q12W).”
> “Mean time-normalized monthly attack rates decreased by 83% in the 600 mg Q24W group, 96% in the 300 mg Q24W group, and 93% in the 300 mg Q12W group”
> “Attack-free rates over Day 29 to 169 were 50% (4/8), 75% (6/8), and 62.5% (5/8) in the 600 mg Q24W, 300 mg Q24W, and 300 mg Q12W groups, respectively.”
> “In the PKK-evaluable population (n=19), mean plasma PKK reductions at Day 169 were 86%, 85%, and 94% in the 600 mg Q24W, 300 mg Q24W, and 300 mg Q12W groups, respectively.”

Source: [Argo Biopharma (2026)](https://www.prnewswire.com/news-releases/argo-biopharma-to-present-positive-phase-ii-updated-results-of-sirna-therapeutic-bw-20805-for-hae-at-bradykinin-symposium-2026-302869556.html)

<a id="topic-2.1.2.14-9"></a>

###### Lonvoguran ziclumeran: KLKB1 gene knockout

> “NTLA-2002 is a wholly owned, investigational in vivo CRISPR-based therapy designed to knock out the KLKB1 gene in the liver”

Source: [Intellia Therapeutics (2025)](https://www.sec.gov/Archives/edgar/data/0001652130/000095017025028373/ntla-ex99_1.htm)

| Outcome | NTLA-2002 25 mg | NTLA-2002 50 mg | Placebo |
| --- | --- | --- | --- |
| Plasma kallikrein change from baseline, week 16 | “-55%” | “-86%” | “2%” |

Source: [Intellia Therapeutics investor presentation (2024)](https://www.intelliatx.com/wp-content/uploads/Intellia_NTLA-2002-Phase-2-Data-Investor-Presentation_10.24.24_vF.pdf)

<a id="topic-2.1.2.14-10"></a>

###### Network meta-analysis of approved prophylactic agents: time-normalized attack rate

> “Additional relative effect estimates showed a statistically significant reduction in the rate of attacks for garadacimab compared with every treatment other than lanadelumab 300 Q2W (Fig. 8).”
> “Lanadelumab 300 Q2W showed statistically significant reductions compared with lanadelumab 300 Q4W, berotralstat, and placebo (Fig. 8).”

Source: [Walsh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12185836/)

| Treatment | Probability of being best (%) | SUCRA (%) |
| --- | --- | --- |
| Garadacimab 200 mg once monthly | “73” | “94” |
| Lanadelumab 300 mg every 2 weeks | “26” | “83” |
| Subcutaneous C1INH 60 IU/kg twice weekly | “1” | “62” |
| Lanadelumab 300 mg every 4 weeks | “0” | “40” |
| Berotralstat 150 mg once daily | “0” | “20” |

Source: [Walsh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12185836/)

<a id="topic-2.1.2.14-11"></a>

###### Network meta-analysis of approved prophylactic agents: attack-free participants

> “The fixed-effect model showed that four active treatments, garadacimab, lanadelumab 300 Q2W, lanadelumab 300 Q4W, and subcutaneous C1INH, statistically significantly increased the proportion of attack-free patients compared with placebo (Fig. 9).”
> “Additional relative effect estimates between the active treatments did not demonstrate statistically significant results (Fig. 10).”

Source: [Walsh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12185836/)

<a id="topic-2.1.2.14-12"></a>

###### Network meta-analysis of lanadelumab and berotralstat: attack rate per 28 days

> “In this NMA, lanadelumab 300 mg administered every 2 weeks or every 4 weeks was associated with statistically significantly higher effectiveness versus berotralstat 150 mg once daily (q.d.) or 110 mg q.d. for both efficacy outcomes assessed.”

Source: [Watt et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10402909/)

| Comparison | Rate ratio (95% CI); p-value |
| --- | --- |
| Lanadelumab 300 mg every 2 weeks vs berotralstat 150 mg once daily | “0.23 (0.10, 0.55); p = 0.0009” |
| Lanadelumab 300 mg every 2 weeks vs C1-INH 1000 IU twice weekly | “0.27 (0.11, 0.64); p = 0.0032” |
| Lanadelumab 300 mg every 2 weeks vs placebo | “0.13 (0.06, 0.29); p < 0.0001” |
| Lanadelumab 300 mg every 4 weeks vs berotralstat 150 mg once daily | “0.48 (0.25, 0.94); p = 0.0311” |
| Lanadelumab 300 mg every 4 weeks vs placebo | “0.27 (0.15, 0.47); p < 0.0001” |

Source: [Watt et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10402909/)

<a id="topic-2.1.2.14-13"></a>

###### Cross-trial comparison limitations

> “There are risks inherent in conducting cross-study comparisons and the results should be interpreted with caution.”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

> “Following the assessment of NMA feasibility, residual heterogeneity between trials may have persisted, despite our best efforts to minimize bias by excluding insufficiently similar trials and/or trial data.”
> “All trials were placebo controlled, rather than head-to-head, which further simplified network structures.”
> “These network characteristics increase the potential for biased treatment effect estimates, which limits the robustness of the analysis.”

Source: [Walsh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12185836/)

> “NMAs cannot be a substitute for head-to-head comparisons”

Source: [Watt et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10402909/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Inheritance pattern

> “an autosomal dominant pattern”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.1-2"></a>

###### Definition: recurrent bradykinin-mediated angioedema

> “Angioedema is a localized, self-limiting, asymmetric, and disfiguring non-inflammatory edema of the subcutaneous and submucosal tissues that arises because of increased vascular permeability.”
> “HAE comprises a group of genetic disorders characterized by recurrent episodes of angioedema, inherited across generations and typically mediated by bradykinin.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.1-3"></a>

###### Etiology: dysfunction or lack of C1 esterase inhibitor

> “Hereditary angioedema (HAE) is a rare disease caused by dysfunction or lack of the C1 esterase inhibitor (C1-INH) protein.”

Source: [Fisch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39827848/)

<a id="topic-2.2.1.1-4"></a>

###### Classification: HAE with C1-INH deficiency (types 1 and 2) and HAE with normal C1-INH

> “HAE (ORPHA:91378, OMIM: PS106100) is most commonly caused by a deficiency of C1 inhibitor (C1-INH), which can be confirmed through biochemical and genetic testing.”
> “It is subclassified into type 1 HAE (quantitative deficiency) and type 2 HAE (dysfunctional protein).”
> “Furthermore, in 2000, a new type of HAE was described in patients with normal C1-INH function, a form initially known as HAE type 3 but currently called HAE with normal C1-INH (HAE-nC1-INH).”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.1-5"></a>

###### Genetic cause: SERPING1 and F12 variants

> “Variants (also called mutations) in the SERPING1 gene cause hereditary angioedema due to C1-INH deficiency.”
> “SERPING1 gene variants that cause hereditary angioedema due to C1-INH deficiency type I lead to reduced levels of C1-INH in the blood, while variants that cause type II result in the production of a C1-INH protein that functions abnormally.”
> “Variants in the F12 gene cause most cases of hereditary angioedema with normal C1-INH.”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.1-6"></a>

###### Penetrance, transmission risk, and de novo variants

> “HAE-C1-INH is an autosomal dominant disorder characterized by high penetrance, with only about 5% of mutation carriers remaining asymptomatic over their lifetime.”
> “The risk of parent–child transmission is 50%, but up to 25% of cases result from de novo genetic mutations.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.1-7"></a>

###### Distribution of HAE types: Swedish population-based cohort

> “Out of the 239 individuals, the majority had HAE type 1 (90.4%) while 9.6% where characterized as HAE type 2.”

Source: [Sundler Björkman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967273/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Hereditary angioedema

<a id="topic-2.2.1.2.1-1"></a>

###### Annual incidence of diagnosed HAE type 1 and 2: Finnish national register

> “In Finland, 103 new patients were diagnosed with HAE-1/2 within the 10-year study period.”
> “The mean incidence of HAE-1/2 was 0.16/100,000, showing an annual variability between 0.07 and 0.22/100,000 (4 to 12 new cases annually)”
> “In our study the incidence seemed quite stable, especially considering that HAE is a rare disease, and a few new patients (e.g. a new HAE family) have a big impact on the calculated annual incidence in a small country like Finland.”

Source: [Sandberg et al. (2024)](https://medicaljournalssweden.se/actadv/article/download/24176/46018/110086)

<a id="topic-2.2.1.2.1-2"></a>

###### Incidence of treated HAE: Swedish National Prescribed Drug Register, 2024

> “The total number of patients treated for HAE has increased from 188 to 245 patients between 2021 and 2024.”
> “This corresponds to a prevalence and incidence rate of 2.31/100,000 and 0.36/100,000 in 2024, respectively.”
> “The observed prevalence aligns with prior estimates, though the incidence, when measured as number of new patients treated for HAE, is higher than what has been observed elsewhere.”

Source: [Danielsson et al. (2025)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2025/poster-session-2-2/current-use-of-hereditary-angioedema-hae-treatments-in-sweden-an-analysis-of-the-national-prescribed-drug-register)

<a id="topic-2.2.1.2.1-3"></a>

###### Incidence across ethnic groups

> “No significant differences in the incidence of C1-INH deficiency across ethnic groups have been confirmed.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Hereditary angioedema

<a id="topic-2.2.1.2.2-1"></a>

###### Epidemiology

> “Hereditary angioedema is estimated to affect 1 in 50,000 people worldwide.”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.2.2-2"></a>

###### Prevalence and incidence: systematic literature review

> “Diagnostic methodology varied greatly, with a minority of studies citing an established guideline.”

Source: [Craig et al. (2026)](https://karger.com/iaa/article/doi/10.1159/000553023/953095/Prevalence-and-Incidence-of-Hereditary-Angioedema)

<a id="topic-2.2.1.2.2-3"></a>

###### Pooled diagnosed annual prevalence: combined HAE types and 95% confidence interval

> “1.70 per 100,000 (1.58–1.83; combined types).”

Source: [Craig et al. (2026)](https://karger.com/iaa/article/doi/10.1159/000553023/953095/Prevalence-and-Incidence-of-Hereditary-Angioedema)

<a id="topic-2.2.1.2.2-4"></a>

###### Pooled diagnosed annual prevalence by HAE type and by region

> “Pooled diagnosed annual prevalence estimates (95% confidence interval) were 1.31 per 100,000 (0.83–2.08; type I HAE), 0.20 per 100,000 (0.14–0.29; type II HAE), 0.06 per 100,000 (0.01–0.40; HAE with normal C1-inhibitor [INH])”
> “Pooled estimates by region were 1.43 per 100,000 (0.99–2.08) and 1.64 per 100,000 (1.02–2.64) in North America and Europe, respectively, which were higher than individual estimates from the other regions.”

Source: [Craig et al. (2026)](https://karger.com/iaa/article/doi/10.1159/000553023/953095/Prevalence-and-Incidence-of-Hereditary-Angioedema)

<a id="topic-2.2.1.2.2-5"></a>

###### United States prevalence of all HAE types: commercial claims database, 2018 to 2020

> “No US prevalence for all types of HAE has been estimated.”
> “For 2018, 2019, and 2020, the claims-based algorithm yielded overall annual unadjusted HAE prevalence estimates per 100,000 and number of people diagnosed with HAE of 2.67, 9559; 2.61, 9341; and 2.43, 8694, respectively.”
> “The corresponding estimates based on expert physician analysis were 2.13, 7602; 2.03, 7275; and 1.84, 6595, respectively.”
> “Our calculations (which exceed the frequently cited 2:100,000 prevalence for HAE with C1 inhibitor deficiency) afford a real-world projected prevalence encompassing all types of HAE.”

Source: [Castaldo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40414286/)

<a id="topic-2.2.1.2.2-6"></a>

###### Worldwide pooled prevalence: systematic review and meta-analysis of 24 studies

> “Twenty-four studies from 2000 to 2024 were included in the analysis, describing 11,245 cases of HAE.”
> “The pooled prevalence of HAE was 1.22 cases per 100,000 people (95% confidence interval [CI]: 0.91, 1.53), with lower prevalences reported in Asia and Africa compared to Europe and North America.”
> “HAE type 1 made up most of the cases, with a slight female predominance.”

Source: [Fisch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39827848/)

<a id="topic-2.2.1.2.2-7"></a>

###### Prevalence of diagnosed HAE type 1 and 2: Finnish national register

> “The prevalence of HAE-1/2 patients increased over the follow-up time from 0.8 to 2.6/100,000 persons, equalling 144 patients at the end of 2021.”
> “The prevalence of 2.6 per 100,000 at the end of 2021 in Finland is higher than the 1.5 per 100,000 that has been observed in the other Nordic countries including Sweden, Denmark, and Norway”

Source: [Sandberg et al. (2024)](https://medicaljournalssweden.se/actadv/article/download/24176/46018/110086)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Age at symptom onset

> “Symptoms of hereditary angioedema typically begin in childhood and worsen during puberty.”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.3-2"></a>

###### Long-term course: onset age, symptom-free years, and severity by sex

> “Clinical symptoms started at a mean age of 11.2 (SD 7.7) years.”
> “During the following cumulative 5736 years, only 370 (6.5%) symptom-free years occurred.”
> “On average, women had a more severe course of the disease than men.”
> “Patients with early onset of clinical symptoms were affected more severely than those with late onset.”

Source: [Bork et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16490473/)

<a id="topic-2.2.1.3-3"></a>

###### Course of an attack and attack frequency without treatment

> “The episodes typically involve nonpruritic, nonpitting swelling that worsens over the first 24 hours and gradually subsides over the next 48 to 72 hours, usually lasting no more than 5–7 days.”
> “Untreated patients with HAE may experience attacks every 7–14 days on average, although some report attacks as frequently as every 3 days, while others may experience them rarely or never.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.3-4"></a>

###### Mortality from laryngeal attacks: German cohort of 728 patients

> “Of the 214 patients who had died, 70 asphyxiated during a laryngeal attack.”
> “Mortality by asphyxiation was higher in patients with undiagnosed HAE-C1-INH (63 cases) than in patients with diagnosed HAE-C1-INH (7 cases).”

Source: [Bork et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22841766/)

<a id="topic-2.2.1.3-5"></a>

###### Mortality from laryngeal attacks: Brazilian reference-center cohort of 433 patients

> “A total of 75 fatal events were evaluated.”
> “Only 10 of 75 patients were given the diagnosis of HAE before death, and the HAE diagnosis was made after death in 65 of 75 patients using verbal autopsy.”
> “The final cause of death after the investigation was asphyxiation owing to LE in 39 of 75 (52%) and deaths owing to other causes in 36 of 75 (48%).”
> “The life span of patients who died of LE was reduced by 20 years compared with those who died of other causes.”

Source: [Minafra et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/35526778/)

<a id="topic-2.2.1.3-6"></a>

###### Mortality from laryngeal edema: review of 23 real-world studies

> “The analyzed studies included 3292 patients and 411 deaths from asphyxia due to laryngeal edema.”
> “Death rates from laryngeal edema had an average of one death for every 20 patients.”
> “The percentage among deaths in general associated with laryngeal edema was evaluated in three studies (32.7%, 44.4%, and 56%).”

Source: [Minafra et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/34687444/)

<a id="topic-2.2.1.3-7"></a>

###### United States death certificates, 1979 to 2010

> “The age-adjusted death rate for hereditary angioedema decreased from 0.28 (95% confidence interval [CI] 0.25-0.32) to 0.06 (95% CI 0.05-0.08) per million persons per year.”
> “Lack of specific coding for acquired angioedema most likely explains the observed association between cancer and hereditary angioedema.”

Source: [Kim et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25280464/)

<a id="topic-2.2.1.3-8"></a>

###### Family deaths from HAE attacks: US patient registry

> “Morbidity surrogates including emergency department visits, hospitalizations, unnecessary abdominal surgeries, and intubations were strikingly high as was mortality with 36.9% of HAE-C1INH and 15.4% of HAE-nl-C1INH participants reporting family members who died from a HAE attack.”

Source: [Christiansen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37619776/)

<a id="topic-2.2.1.3-9"></a>

###### All-cause mortality: Swedish population-based cohort

> “In the current study, there was no increased risk of death (OR 0.69; 95% CI 0.38–1.26) among HAE patients.”
> “Nonetheless, the mortality among HAE patients during the last decade seems to be low.”

Source: [Sundler Björkman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967273/)

<a id="topic-2.2.1.3-10"></a>

###### Rising prevalence attributed to decreased mortality: Finnish national register

> “The rise in yearly prevalence is likely a combination of stable incidence and decreased mortality, e.g. due to more effective HAE treatment options”

Source: [Sandberg et al. (2024)](https://medicaljournalssweden.se/actadv/article/download/24176/46018/110086)

<a id="topic-2.2.1.3-11"></a>

###### Factors associated with in-hospital mortality: US Nationwide Inpatient Sample, 2021

> “Older HA patients and those with autoimmune conditions, hypertension, or low income were at higher risk of mortality.”

Source: [Khalid and Hitch (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12276015/)

<a id="topic-2.2.1.3-12"></a>

###### Risk of death from laryngeal edema without a diagnosis

> “In the absence of the HAE diagnosis, the risk of death with laryngeal edema is estimated at 20%–25%.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Pathophysiology

> “Hereditary angioedema (HAE) is characterized by C1 esterase inhibitor (C1INH) deficiency, leading to uninhibited kallikrein-kinin system (KKS) activation and bradykinin production resulting in angioedema attacks”

Source: [Intellia Therapeutics AAAAI poster (2026)](https://www.intelliatx.com/wp-content/uploads/AAAAI-2026_KKS-Modeling-Poster_with-Supplement.pdf)

<a id="topic-2.2.1.4-2"></a>

###### Bradykinin generation: activation of prekallikrein to plasma kallikrein

> “In HAE-C1-INH, bradykinin is the primary mediator of swelling.”
> “This molecule arises from cleavage of high-molecular-weight kininogen by plasma kallikrein, which is activated from prekallikrein by factor XII.”
> “The resulting bradykinin nonapeptide increases vascular permeability and induces swelling (angioedema) through a specific receptor, B2”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.4-3"></a>

###### Role of C1 inhibitor in regulating the kallikrein-kinin system

> “C1-INH is a serine protease inhibitor protein synthesized in hepatocytes that is crucial in regulating the plasma kallikrein–kinin system (KKS) and preventing excessive bradykinin production.”
> “HAE-C1-INH is caused by mutations in SERPING1, which encodes C1-INH, leading to reduced levels or impaired activity of C1-INH.”
> “This deficiency in turn leads to uncontrolled activation of the KKS and excessive bradykinin production, with bradykinin acting as the key mediator of the condition.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.4-4"></a>

###### Bradykinin and vascular permeability

> “When the body does not have enough normal C1-INH protein, it ends up with excessive amounts of a protein fragment (peptide) called bradykinin.”
> “Bradykinin promotes inflammation by increasing the amount of fluid that leaks through the walls of blood vessels into body tissues (vascular permeability).”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.4-5"></a>

###### Plasma prekallikrein as the target of onvuzosiran

> “Hereditary angioedema (HAE) is a rare genetic disorder caused by dysregulation of the plasma kallikrein pathway, leading to recurrent, unpredictable attacks of swelling that can be painful, disabling, and life-threatening.”
> “ADX-324 is an investigational siRNA therapy designed to inhibit prekallikrein (PKK) generation at the mRNA level and reduce the production of plasma PKK, thereby averting bradykinin generation and potentially preventing HAE attacks.”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Diagnostic testing

> “Measurements of serum/plasma levels of C1–INH function, C1–INH protein, and C4 are used to diagnose HAE-1/2”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="topic-2.2.1.5-2"></a>

###### Systematic literature review of HAE disease burden: diagnostic delay

> “The mean or median delay from the first onset of a symptom of HAE to confirmed diagnosis ranged from 3.9 to 26 years.”

Source: [Guan et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03265-z)

<a id="topic-2.2.1.5-3"></a>

###### Guideline recommendation: initial C1-INH functional assay

> “We recommend that all patients for whom HAE is suspected undergo an initial assessment with a C1-INH functional assay, as long as it is performed by a specialized laboratory using an accurate, validated method.”
> “If the C1-INH functional assay is unavailable or unreliable, the diagnosis can still be confirmed through quantitative C1-INH measurement and/or genetic testing for SERPING1.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.5-4"></a>

###### Laboratory findings: C4, C1-INH antigen, and C1-INH function

> “C4 levels are low in 90%–95% of patients with HAE-C1-INH during asymptomatic periods and are almost always low during acute attacks.”
> “In HAE type 1, C1-INH antigen levels are reduced, whereas in HAE type 2, they are normal or elevated.”
> “In HAE-C1-INH, functional activity is typically less than 50% of normal levels.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.5-5"></a>

###### Guideline recommendations: genetic testing and cascade family testing

> “We recommend genetic testing for HAE-nC1-INH in patients for whom there is high clinical suspicion of HAE and who have normal C1-INH functional assay results.”
> “We recommend cascade family testing for HAE when an index case is diagnosed, either through C1-INH testing or genetic testing, as appropriate based on age and diagnosis (HAE-C1-INH vs. HAE-nC1-INH).”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.5-6"></a>

###### Diagnostic delay over time

> “Fortunately, diagnostic delay in HAE has declined considerably in the last decades, from an average of 21 years in the 1970s to around 7–10 years currently”
> “Under 40% of patients receive a diagnosis within 1 to 3 years after symptom onset.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.5-7"></a>

###### Diagnostic delay: US patient registry

> “Delay to diagnosis was shorter in HAE-C1INH (5 vs 11 years), but both had decreasing delays over time.”

Source: [Christiansen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37619776/)

<a id="topic-2.2.1.5-8"></a>

###### Age at diagnosis and diagnoses preceding HAE: Finnish national register

> “Mean age at the time of diagnosis was 39 years, with 22.5% diagnosed at ≤18 years, and 13.6% before or at the age of 12.”
> “Of note, 37% had a diagnosis of angioedema before the first HAE diagnosis, 17% a diagnosis of oedema, whereas 6% had been diagnosed with urticaria, suggesting misdiagnosed HAE or unrelated urticaria.”

Source: [Sandberg et al. (2024)](https://medicaljournalssweden.se/actadv/article/download/24176/46018/110086)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Cutaneous swelling: hands, feet, and face

> “HAE is a very rare and potentially life-threatening genetic condition involving swelling of various parts of the body, hands, feet, or face.”

Source: [US Hereditary Angioedema Association](https://www.haea.org/)

<a id="topic-2.2.1.6-2"></a>

###### Gastrointestinal symptoms: intestinal attacks

> “severe abdominal pain, nausea, and vomiting.”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.6-3"></a>

###### Airway symptoms: obstruction risk

> “can restrict breathing and lead to life-threatening obstruction of the airway.”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.6-4"></a>

###### Distribution of attacks by site: edema episodes reported by 221 patients

> “Skin swellings, including extremity, facial, genital, and trunk swellings, and abdominal attacks occurred in 97.4% of all edema episodes of the disease.”
> “The other episodes were laryngeal edema (0.9%); edema of the soft palate (0.6%); tongue swellings (0.3%); headache episodes (0.7%); episodes affecting urinary bladder (0.3%), chest (0.2%), muscles (0.4%), joints (0.1%), kidneys (0.1%), and esophagus (0.05%), and were partly combined with other edema episodes.”

Source: [Bork et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16490473/)

<a id="topic-2.2.1.6-5"></a>

###### Abdominal and laryngeal involvement: proportion of patients affected

> “Abdominal involvement occurs in 70%–90% of all individuals and is associated with high morbidity.”
> “Laryngeal involvement, although accounting for less than 1% of all attacks, poses a risk of death and occurs at least once in about half of patients.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.6-6"></a>

###### Airway symptoms: phases of fatal laryngeal attacks

> “Phase 1, the predyspnea phase, lasted on average for 3.7 ± 3.2 hours (range, 0-11 hours).”
> “Phase 2, the dyspnea phase, lasted on average for 41 ± 49 minutes (range, 2 minutes to 4 hours).”

Source: [Bork et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22841766/)

<a id="topic-2.2.1.6-7"></a>

###### Prodromal symptoms and erythema marginatum

> “Non-specific prodromal symptoms are common and can include anxiety, nausea, paresthesia, and fatigue.”
> “One third of patients with HAE, especially children, experience erythema marginatum (a nonpruritic form of flat, figurate erythema) as an initial manifestation, which may mimic the skin lesions of urticaria.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Consequences of abdominal attacks

> “abdominal attacks may lead to unnecessary surgeries or opiate dependence.”

Source: [Henao et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4859422/)

<a id="topic-2.2.1.7-2"></a>

###### Cardiovascular, thromboembolic, and autoimmune comorbidity: Swedish population-based cohort

> “Increased risk of cardiovascular disease (odds ratio [OR] 1.83; 95% confidence interval [CI] 1.32–2.54), including arterial (OR 6.74; 95% CI 1.89–24.06) and venous thromboembolic disease (OR 4.20; 95% CI 2.42–7.23) as well as hypertension (OR 1.64; 95% CI 1.12–2.39) was seen in HAE.”
> “Furthermore, the risk of autoimmune disease was increased (OR 1.65; 95% CI 1.15–2.35) being particularly pronounced for systemic lupus erythematosus (OR 71.87; 95% CI 8.80–586.7).”
> “In contrast, the risk of cancer was not increased.”
> “A two-fold higher prevalence of allergy, asthma, and atopic dermatitis was found (OR 2.19; 95% CI 1.60–2.99).”

Source: [Sundler Björkman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967273/)

<a id="topic-2.2.1.7-3"></a>

###### Comorbidity associated with attenuated androgen prophylaxis

> “Side effects of attenuated androgens can contribute to comorbidities in HAE since long-term use of danazol is associated with increases in atherogenic indices.”

Source: [Sundler Björkman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967273/)

<a id="topic-2.2.1.7-4"></a>

###### Composite venous thromboembolism: reanalysis of the Swedish cohort

> “Our analysis revealed that individuals with HAE had a significantly increased risk of composite VTE compared to controls (odds ratio 3.57, 95% confidence interval 2.16-5.81, Figure 1A).”
> “In contrast, individuals with HAE did not have a significantly increased risk of composite ATE (odds ratio 1.3, 95% confidence interval 0.81-2.09, Figure 2B).”
> “C1INH is a potent inhibitor of plasma kallikrein, which spans the kallikrein kinin pathway and intrinsic coagulation pathway, and the intrinsic coagulation pathway components activated factor XII and activated factor XI”

Source: [Grover et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12541594/)

<a id="topic-2.2.1.7-5"></a>

###### Comorbidity compared with the general US population: US patient registry

> “Females with HAE-C1INH had a significant increase in the prevalence of depression, sleep disorders, kidney disease, anemia, and hepatitis.”
> “Cardiovascular comorbidities were significantly reduced in the HAE-C1INH group.”

Source: [Christiansen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37619776/)

<a id="topic-2.2.1.7-6"></a>

###### Consequences of delayed diagnosis

> “Delays in HAE diagnosis can lead to serious consequences, including reduced quality of life (QoL), loss of productivity and income, depression, unnecessary medical interventions, increased healthcare costs, and an imminent risk of death.”
> “Unnecessary abdominal surgeries, such as appendectomies, along with exploratory diagnostic procedures such as colonoscopy, also are frequent.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Hereditary angioedema

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Burden of disease in adults: multinational survey

> “In the survey, participants reported 11.5 ± 14.2 HAE attacks (mean ± SD) in the past 6 months.”

Source: [Watt et al. (2026)](https://link.springer.com/article/10.1186/s13023-025-04134-z)

<a id="topic-2.2.1.8.1-2"></a>

###### Multinational adult survey: treatment exposure and quality-of-life outcomes

| Measure | Reported result |
| --- | --- |
| Participants included | “260” |
| Participants using any long-term prophylaxis | “153 (58.8%)” |
| First-line prophylaxis among prophylaxis users, per study classification | “56/153 (36.6%)” |
| AE-QoL total score, mean ± SD | “42.9 ± 23.2” |
| Participants with AE-QoL total score ≥39 | “137 of 260 (52.7%)” |
| Moderate to severe anxiety by HADS | “69 (26.5%)” |
| Moderate to severe depression by HADS | “27 (10.4%)” |

Source: [Watt et al. (2026)](https://link.springer.com/article/10.1186/s13023-025-04134-z)

<a id="topic-2.2.1.8.1-3"></a>

###### Patient preferences for long-term prophylaxis: discrete-choice experiment

> “A reduction in attack frequency is the most important treatment feature for adults living with hereditary angioedema.”

Source: [Villa et al. (2026)](https://link.springer.com/article/10.1007/s40271-025-00798-8)

<a id="topic-2.2.1.8.1-4"></a>

###### Health-related quality of life, depression, and work productivity: US patient survey

> “A total of 457 HAE patients responded to the survey (response rate, ∼19%).”
> “Patients reported significantly poorer health-related quality of life versus population norms, based on the SF-12 Physical Component Summary (mean, 43.7 versus 49.6; p < 0.001) and Mental Component Summary (mean, 42.6 versus 49.4; p < 0.001).”
> “HAE patients also had higher mean HDI-SF scores than population norms (8.1 ± 6.5 versus 3.1 ± 3.0; p < 0.001), with 42.5% of HAE patients scoring >8.5, indicative of depressive symptomatology.”
> “Productivity was also markedly impaired in all WPAI-GH categories, including 34% overall work impairment.”
> “Because of their most recent HAE attack, workers lost a mean of 3.3 days; students lost a mean of 1.9 days.”

Source: [Lumry et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20929608/)

<a id="topic-2.2.1.8.1-5"></a>

###### Anxiety and depression: health technology assessment background

> “Studies have shown that almost three-quarters of HAE patients noted that the disease had a significant impact on their quality of life, including anxiety (15% of patients) and depression (almost 40% of patients) related to their ability to carry out daily activities, fear of attacks, and concerns about transmission of the condition to their children.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-2.2.1.8.1-6"></a>

###### Quality of life with subcutaneous prophylaxis compared with on-demand treatment alone: US patient survey

> “The greatest improvement in QoL was seen in patients who used novel SC prophylactic therapies, with a 59.5% (p < 0.01) improvement in median impairment scores versus on-demand–only treatment.”
> “In addition, patients who used novel SC prophylactic therapies reported a 77% reduction in the number of attacks each year when compared with those who used on-demand–only treatment.”

Source: [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/)

<a id="topic-2.2.1.8.1-7"></a>

###### Burden despite current therapies: US adult survey

> “A web-based survey was conducted from March to April 2025 among 100 US adults with HAE-C1INH currently receiving long-term prophylaxis and/or on-demand therapies.”
> “Even with treatment, 80% of respondents reported ≥1 HAE attack in the past year and 61% thought about HAE at least weekly.”
> “Mental health was the aspect that respondents felt was most impacted by HAE (54% of respondents), and 73% reported taking ≥2 measures to avoid attack triggers.”
> “Several concerns impacted the ability to reach normalization; lifetime use of medication was the most commonly reported concern (68% of respondents).”
> “The greatest unmet needs associated with long-term prophylaxis were cost- and access-related.”

Source: [Busse et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41698689/)

<a id="topic-2.2.1.8.1-8"></a>

###### Preferences for long-term prophylaxis and willingness to switch: US adult survey

> “A total of 150 individuals completed the survey.”
> “Respondents rated effectiveness in preventing attacks and reducing the severity of attacks as the most important LTP attributes.”
> “Route of administration and convenience were more than twice as important as dosing frequency.”
> “Individuals preferred oral daily therapy to biweekly (54% vs 46%) or monthly injections (54% vs 46%).”
> “Most individuals (71%) were at least somewhat willing to switch LTP treatments in the next 6 months, particularly those whose HAE was not well controlled, were anxious about taking LTP, were burdened by treating their HAE, or preferred oral administration.”

Source: [Olson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41429313/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Drug patterns and economic costs

> “Notably, annualized expenditures for ODT prescriptions, hospitalizations, and ED visits averaged >$200,000, even after initiation of SC LTP.”

Source: [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/)

<a id="topic-2.2.1.8.2-2"></a>

###### Healthcare costs and resource utilization before and after starting long-term prophylaxis: US commercial claims

> “A total of 328 patients were included in this analysis.”
> “Most patients (67%) had ≥1 post-index on-demand therapy claim.”
> “During follow-up, 17% and 8% had ≥1 HAE-related ER and inpatient visit, respectively.”
> “Mean annualized total HAE-related healthcare costs per patient were $165,348 pre-LTP and $515,333 post-LTP, driven by increased LTP pharmacy costs (mean $395,845 PPPY) and partially offset by reductions in medical costs (ER/inpatient, mean $8344 PPPY).”
> “This study found that 55% of patients had refill gaps in LTP claims, discontinued, or switched LTP within a year of initiation.”

Source: [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/)

<a id="topic-2.2.1.8.2-3"></a>

###### Healthcare costs with lanadelumab compared with berotralstat: US claims

> “Fifty-seven lanadelumab- and 32 berotralstat-treated patients were included.”
> “Total HAE treatment costs were similar during months 0–6 (lanadelumab, $377,326 vs berotralstat, $373,010), but decreased in months 7–12 ($319,967) and 13–18 ($283,241) of lanadelumab.”
> “On-demand treatment/short-term prophylaxis costs were lower for lanadelumab across the three follow-up periods than for berotralstat during months 0–6 (berotralstat, $60,451; lanadelumab, months 0–6, $46,336, months 7–12, $37,578, months 13–18, $23,968).”
> “all dollar estimates were inflated to 2022 dollars using the medical care component of the Consumer Price Index.”

Source: [Princic et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11963383/)

<a id="topic-2.2.1.8.2-4"></a>

###### Treatment costs over time with lanadelumab: US claims

> “Fifty-four lanadelumab users were included; 25 (46%) had evidence of down titration.”
> “Lanadelumab costs decreased from $316,724 to $269,861 to $246,919 in months 0-6, 7-12, and 13-18, respectively (p < .01); total HAE treatment costs decreased from $377,076 to $329,855 to $286,074 in months 0-6, 7-12, and 13-18, respectively (p < .01).”

Source: [Shah et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37395381/)

<a id="topic-2.2.1.8.2-5"></a>

###### Direct and indirect costs of on-demand treatment alone: US patient survey

> “Per patient/year direct costs associated with modeled on-demand–only treatment totaled $363,795, with additional indirect socioeconomic costs of $52,576 per patient/year.”
> “Medications comprise the largest component (62.5%) of modeled on-demand–only treatment, at an estimated $227,674 per patient per year.”
> “The second highest component cost was hospitalization for treatment of an HAE attack (22.1%), followed by ED visits (12.5%).”

Source: [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/)

<a id="topic-2.2.1.8.2-6"></a>

###### Annual per-patient costs by attack severity before current prophylactic agents: US patient survey

> “Total annual per-patient costs are estimated at $42,000 for the average HAE patient, with costs totaling $14,000 for patients with mild attacks, $27,000 for patients with moderate attacks, and $96,000 for patients with severe attacks.”
> “Hospital costs account for 67% of direct medical costs.”
> “Respondents reported high rates of missed work, lost productivity, and lost income, contributing to indirect costs totaling $16,000 annually for the average patient.”

Source: [Wilson et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20408341/)

<a id="topic-2.2.1.8.2-7"></a>

###### Resource use after insurance delays or denials of prophylaxis

> “A total of 70% of participants reported an increased frequency of angioedema attacks resulting from insurance delays or denials.”
> “Twenty-five percent of respondents reported more urgent care or emergency department visits.”

Source: [Arora et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37558360/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Hereditary angioedema on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Income loss from work missed because of attacks

> “missed work because of acute attacks resulted in an income loss of $3402 annually”

Source: [Guan et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03265-z)

<a id="topic-2.2.1.8.3-2"></a>

###### Caregiver productivity costs: US patient and caregiver survey

> “For those respondents who indicated that they were either patients or caregivers or solely caregivers, the fact that they would no longer have to take time off work or could participate in the labor force, or be more productive while at work, accounted for $7630 (14.5%).”

Source: [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/)

<a id="topic-2.2.1.8.3-3"></a>

###### Caregiver time off work

> “Caregivers, often parents of children with HAE, may also need to take time off work to care for an HAE patient.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Genetic testing: cost and limited routine necessity

> “genetic testing can be costly, time-consuming, and rarely necessary.”

Source: [Henao et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4859422/)

<a id="topic-2.2.1.8.4-2"></a>

###### Medicare payment rates for complement antigen and functional assays

> “2026,86160,,20260101,N,00012.00,Complement antigen”
> “2026,86161,,20260101,N,00012.00,Complement/function activity”

Source: [CMS Clinical Laboratory Fee Schedule (2026)](https://www.cms.gov/files/zip/26clabq4.zip)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 C1 Esterase Inhibitors

<a id="topic-2.2.2.1.1-1"></a>

###### International/Canadian guideline: first-line long-term prophylaxis options

> “Berotralstat, donidalorsen, garadacimab, lanadelumab, or pdC1INH could be used as first-line therapy for long-term prophylaxis in patients with HAE due to C1INH deficiency.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.1.1-2"></a>

###### Subcutaneous plasma-derived C1 inhibitor: indication and dosing

> “HAEGARDA is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) (C1-INH) indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older.”
> “Administer 60 International Units per kg body weight twice weekly (every 3 or 4 days).”

Source: [CSL Behring (2022)](https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf)

<a id="topic-2.2.2.1.1-3"></a>

###### Intravenous plasma-derived C1 inhibitor: indication and dosing

> “CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents, and pediatric patients (6 years of age and older) with Hereditary Angioedema (HAE).”
> “1,000 IU Intravenous every 3 or 4 days”
> “Doses up to 2,000 IU (not exceeding 80 IU/kg) every 3 or 4 days may be considered based on individual patient response.”

Source: [FDA (2022)](https://www.fda.gov/media/75907/download)

<a id="topic-2.2.2.1.1-4"></a>

###### Subcutaneous and intravenous routes: guideline comparison

> “SC administration of pdC1-INH results in more consistent plasma C1-INH concentrations than the IV route and mitigates venous access–related complications, such as thrombosis risk.”
> “When first-line treatments are unavailable, IV pdC1-INH (approved for LTP in some countries) is a second-line option, supported by scientific evidence of its efficacy.”
> “However, it has disadvantages, such as the need for venous access, high cost, and frequent administrations due to its short half-life.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Plasma Kallikrein Inhibitors

<a id="topic-2.2.2.1.2-1"></a>

###### Sebetralstat: oral on-demand treatment

> “EKTERLY is a plasma kallikrein inhibitor that is used for the treatment of acute attacks of hereditary angioedema (HAE)”
> “an oral tablet.”

Source: [FDA Drug Trials Snapshot EKTERLY](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-ekterly)

<a id="topic-2.2.2.1.2-2"></a>

###### Lanadelumab: indication and dosing interval

> “TAKHZYRO is a plasma kallikrein inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 2 years and older.”
> “The recommended starting dosage in adult and pediatric patients 12 years of age and older is 300 mg administered subcutaneously every 2 weeks (q2wks).”
> “A dosing interval of 300 mg every 4 weeks (q4wks) is also effective and may be considered if the patient is well-controlled (e.g., attack free) for more than 6 months.”

Source: [FDA TAKHZYRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761090s020lbl.pdf)

<a id="topic-2.2.2.1.2-3"></a>

###### Berotralstat: oral prophylaxis and dosing

> “ORLADEYO is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older.”
> “The recommended dosage of ORLADEYO for adults and pediatric patients 12 years of age and older is 150 mg taken orally once daily with food”
> “ORLADEYO should not be used for treatment of acute HAE attacks.”

Source: [FDA ORLADEYO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214094s006lbl.pdf)

<a id="topic-2.2.2.1.2-4"></a>

###### Lanadelumab and berotralstat: guideline summary of efficacy

> “Lanadelumab, a fully human monoclonal antibody directed against plasma kallikrein, reduces the risk of attacks in the context of LTP, with a low risk of adverse events and a positive impact on QoL.”
> “Reported attack rates with this drug are less than 0.3 per month with biweekly dosing, and over 95% of treatment-emergent adverse events are non-serious.”
> “Berotralstat, an oral plasma kallikrein inhibitor, demonstrated efficacy in a pivotal trial, achieving a ∼50% reduction in attack rate.”
> “Patients should be aware of delayed onset of action.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Bradykinin B2 Receptor Antagonists

<a id="topic-2.2.2.1.3-1"></a>

###### Icatibant: receptor antagonism

> “a specific and selective competitive antagonist of the bradykinin B2 receptor”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Factor XIIa Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

###### Garadacimab: mechanism and maintenance dosing

> “Garadacimab-gxii is an inhibitor of activated FXII”
> “an initial loading dose of 400 mg”
> “200 mg administered subcutaneously every month.”

Source: [FDA ANDEMBRY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761367s000lbl.pdf)

<a id="topic-2.2.2.1.4-2"></a>

###### Garadacimab: approved population and administration

> “ANDEMBRY is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.”
> “ANDEMBRY is intended for self-administration or administration by a caregiver.”

Source: [FDA ANDEMBRY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761367s000lbl.pdf)

<a id="topic-2.2.2.1.4-3"></a>

###### Garadacimab: guideline summary of efficacy

> “It inhibits activated factor XIIa at the top of the kallikrein-kinin pathway.”
> “In the phase 3 Vanguard trial the attack rate was reduced by 87% compared to placebo.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Prekallikrein-directed Antisense Oligonucleotides

<a id="topic-2.2.2.1.5-1"></a>

###### Donidalorsen: prophylaxis and dosing interval

> “DAWNZERA is a prekallikrein-directed antisense oligonucleotide indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE)”
> “every four or eight weeks.”

Source: [FDA Drug Trials Snapshot DAWNZERA](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-dawnzera)

<a id="topic-2.2.2.1.5-2"></a>

###### Donidalorsen: indication, mechanism, and dosing

> “DAWNZERA is a prekallikrein-directed antisense oligonucleotide indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.”
> “The recommended dosage of DAWNZERA is 80 mg administered subcutaneously every 4 weeks.”
> “A dosage of 80 mg administered subcutaneously every 8 weeks may be considered.”
> “Donidalorsen lowers PKK concentration, preventing excessive bradykinin production in patients with HAE.”

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="topic-2.2.2.1.5-3"></a>

###### Donidalorsen: guideline summary of efficacy by dosing interval

> “Donidalorsen is an antisense oligonucleotide that blocks the production of prekallikrein in the liver, which is primarily synthesized in the liver.”
> “Efficacy of every 4- and 8-weeks injections was 81% and 55%, respectively, compared to placebo.”
> “Because of a delay in onset of the donidalorsen, when data were compared to placebo starting at week 5, the 4- and 8-weeks dose reduced attacks by 87% and 60%, respectively.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Attenuated Androgens

<a id="topic-2.2.2.1.6-1"></a>

###### Second-line long-term prophylaxis

> “We recommend the use of androgens only as second-line long-term prophylaxis.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="topic-2.2.2.1.6-2"></a>

###### Second-line position, adverse effects, and monitoring

> “We suggest IV C1-INH, attenuated androgens (at the lowest effective dose, preferably not exceeding 200 mg per day), or antifibrinolytics as second-line options for LTP in patients for whom first-line therapies are not available, not feasible, or not tolerated.”
> “Attenuated androgens are strongly associated with virilization in women, dyslipidemia, and hepatotoxicity, with an increased risk of hepatic neoplasms.”
> “They cannot be used during pregnancy or in the pediatric and adolescent populations because they interfere with growth.”
> “We recommend semi-annual monitoring when using androgens, including a complete blood count, chemistry panel, lipid panel, and routine urinalysis, along with annual liver ultrasound.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Antifibrinolytics

<a id="topic-2.2.2.1.7-1"></a>

###### Tranexamic acid: reported prophylactic responses in HAE-FXII, HAE-PLG, and HAE with normal C1 inhibitor of unknown cause

> “have shown favourable responses to LTP, particularly with tranexamic acid.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.1.7-2"></a>

###### Androgens and antifibrinolytics: restriction on first-line use

> “no longer recommended as first-line options”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.1.7-3"></a>

###### Tranexamic acid: efficacy by HAE type

> “Tranexamic acid shows mediocre efficacy in HAE-C1-INH but performs better in HAE-nC1-INH, particularly in cases involving PLG or FXII variants.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Plasma Replacement

<a id="topic-2.2.2.1.8-1"></a>

###### Fresh frozen plasma: fallback for on-demand treatment

> “treat HAE attacks if none of the FDA-approved on-demand medications are available.”

Source: [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)

<a id="topic-2.2.2.1.8-2"></a>

###### Solvent detergent plasma and fresh frozen plasma: third-line on-demand treatment

> “We recommend SDP/FFP as third-line treatment, with SDP preferred over FFP if available due to a lower risk of viral transmission.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Progestins

<a id="topic-2.2.2.1.9-1"></a>

###### Progestin prophylaxis: variant-specific observational evidence

| Feature | Guideline description |
| --- | --- |
| Subtype with reported responses | “HAE-FXII” |
| Reported response | “Favourable responses” |
| Evidence for other variants | “limited evidence for other HAE-nC1INH variants.” |

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="heading-2.2.2.1.10"></a>

###### 2.2.2.1.10 Supportive Care and Airway Management

<a id="topic-2.2.2.1.10-1"></a>

###### Supportive care when effective on-demand treatment is not available

> “IV fluids, antiemetics, narcotic pain medication, or intubation”

Source: [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)

<a id="topic-2.2.2.1.10-2"></a>

###### Upper airway involvement: guideline recommendations

> “We recommend that in the case of upper airway swelling, ODT should be given as early as possible, and patients should seek emergency care.”
> “We recommend that airway interventions (intubation, cricothyroidotomy, or tracheotomy) be promptly considered during the initial evaluation of patients presenting with signs of upper airway involvement.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="heading-2.2.2.1.11"></a>

###### 2.2.2.1.11 Limitations of Current Therapies

<a id="topic-2.2.2.1.11-1"></a>

###### Summary

- Administration frequency of first-line prophylaxis ranges from twice weekly (subcutaneous plasma-derived C1 inhibitor, every 3 or 4 days) and once daily (oral berotralstat) to every 2 weeks (lanadelumab, with every 4 weeks considered after more than 6 months of good control), monthly after a 400 mg loading dose (garadacimab), and every 4 or 8 weeks (donidalorsen). Intravenous C1 inhibitor requires venous access and has a “high cost” and “frequent administrations due to its short half-life”.
- Attacks “can still occur even in patients under LTP”. Berotralstat achieved an approximately 50% reduction in attack rate in its pivotal trial, and donidalorsen every 4 and 8 weeks reduced attacks by 81% and 55%, respectively, compared with placebo. Berotralstat, lanadelumab, and donidalorsen have a delayed onset of protection.
- In US commercial claims, 55% of patients had refill gaps, discontinued, or switched prophylaxis within a year of initiation, and on-demand treatment use “remained present for over two-thirds of patients”. A second study reported that annualized expenditures for on-demand prescriptions, hospitalizations, and emergency department visits averaged more than $200,000 after subcutaneous prophylaxis began.
- No head-to-head trials of prophylactic agents have been published; a Cochrane review stated that this “prevented us from drawing firm conclusions on the relative efficacy of the drugs”, and indirect comparisons favor lanadelumab and C1 inhibitor over berotralstat.
- About 50% of patients receive long-term prophylaxis, even in high-income countries, and the higher costs of newer agents limit their availability.
- Second-line attenuated androgens are associated with virilization in women, dyslipidemia, and hepatotoxicity, cannot be used in pregnancy or in children and adolescents, and require semi-annual laboratory monitoring with annual liver ultrasound; tranexamic acid shows “mediocre efficacy in HAE-C1-INH”.

Source: [CSL Behring (2022)](https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf); [FDA TAKHZYRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761090s020lbl.pdf); [FDA ORLADEYO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214094s006lbl.pdf); [FDA ANDEMBRY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761367s000lbl.pdf); [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf); [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/); [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/); [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/); [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/); [Beard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9632406/)

<a id="topic-2.2.2.1.11-2"></a>

###### Long-term prevention of attacks: Cochrane review

> “This and the lack of head‐to‐head trials prevented us from drawing firm conclusions on the relative efficacy of the drugs.”

Source: [Beard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9632406/)

<a id="topic-2.2.2.1.11-3"></a>

###### Attacks during prophylaxis and comparative evidence: guideline statements

> “Attacks can still occur even in patients under LTP, and on-demand medication must remain available to them.”
> “Although no direct comparisons between therapies have been published, indirect comparisons and a Cochrane analysis favor lanadelumab and C1-INH as LTP over berotralstat in terms of efficacy.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.1.11-4"></a>

###### Uptake of prophylaxis and cost as a barrier to access

> “Nevertheless, even with recent advances, LTP is still not the standard of care, even in high-income countries, with only about 50% of patients currently receiving it.”
> “Despite their greater effectiveness, newer drugs are associated with higher costs that clearly limit their availability, particularly in low- and middle-income countries.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.1.11-5"></a>

###### Delayed onset of protection: pediatric guideline

> “Note: Berotralstat and lanadelumab have a delayed onset of a few weeks until optimal protective effect is achieved, which should be considered when initiating prophylaxis”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="topic-2.2.2.1.11-6"></a>

###### Persistence, switching, and on-demand use after starting prophylaxis: US claims

> “This study found that 55% of patients had refill gaps in LTP claims, discontinued, or switched LTP within a year of initiation.”
> “Even with use of LTP, on-demand treatment utilization remained present for over two-thirds of patients.”

Source: [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/)

<a id="topic-2.2.2.1.11-7"></a>

###### Drug patterns and economic costs

> “Notably, annualized expenditures for ODT prescriptions, hospitalizations, and ED visits averaged >$200,000, even after initiation of SC LTP.”

Source: [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/)

<a id="topic-2.2.2.1.11-8"></a>

###### Adherence and persistence after starting targeted prophylaxis: US linked health records and claims

> “Primary study measures were adherence, defined as the mean proportion of days covered (PDC), and persistence, defined as having no gap in treatment ≥ 45 days after the LTP initiation date.”
> “The main analysis included 357 patients (90 on berotralstat, 189 lanadelumab, and 78 SC-pdC1-INH).”
> “Adherence (mean PDC) was similar between treatments at 0.73, 0.78, and 0.74 for berotralstat, lanadelumab, and SC-pdC1-INH, respectively.”
> “Proportions of patients persistent on index LTP after 12 months were similar across LTPs: 61%, 58%, and 53% for berotralstat, lanadelumab, and SC-pdC1-INH, respectively.”

Source: [Zuraw et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40300843/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

A 2026 guideline (Vázquez et al.) recommends that all patients with HAE be evaluated for long-term prophylaxis at every visit through shared decision-making, and lists subcutaneous plasma-derived C1 inhibitor, lanadelumab, berotralstat, garadacimab, and donidalorsen as first-line options. The 2026 pediatric guideline recommends lanadelumab or plasma-derived C1 inhibitor for children aged between 6 and 12 years, and adds berotralstat and garadacimab for adolescents aged 12 years or older. Both guidelines recommend supplying on-demand treatment for at least 2 attacks during prophylaxis, and the Vázquez et al. guideline recommends management by physicians with expertise in HAE supported by a referral center.

Onvuzosiran is an investigational small interfering RNA and appears in no guideline list of first-line agents. The sponsor is developing it for prevention of HAE attacks as a subcutaneous injection every 3 or 6 months, both intervals being studied in the phase 3 STOP-HAE trial, and a 2025 review describes it as in development for long-term prophylaxis in HAE type I/II. STOP-HAE requires participants to complete any washout of long-term prophylaxis before screening and to have access to an acute therapy, so its results will describe onvuzosiran as the only long-term prophylactic agent, compared with placebo, with on-demand treatment available. The sources do not state whether onvuzosiran would be self-administered or given by a health care professional; the guideline states that self-administration and home therapy are available for current agents including lanadelumab, garadacimab, and donidalorsen.

Other prophylactic agents in late-stage development include navenibart, a plasma kallikrein inhibitor dosed subcutaneously every 3 or 6 months in a phase 3 trial with top-line results expected in Q3 2027; deucrictibant XR, with an NDA submission planned for the first half of 2027; lonvoguran ziclumeran, intended as a single-dose therapy, with a PDUFA target action date of March 10, 2027; and BW-20805, a second prekallikrein-directed siRNA dosed every 12 or 24 weeks in a study of 25 participants with HAE.

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/); [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/); [Uminski et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12618362/); [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm); [ADARx Pharmaceuticals](https://stophae.com/); [BioCryst Pharmaceuticals (2026)](https://www.sec.gov/Archives/edgar/data/882796/000117184326007097/exh_991.htm); [Pharvaris (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm); [Intellia Therapeutics (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fda-acceptance-biologics-license); [Argo Biopharma (2026)](https://www.prnewswire.com/news-releases/argo-biopharma-to-present-positive-phase-ii-updated-results-of-sirna-therapeutic-bw-20805-for-hae-at-bradykinin-symposium-2026-302869556.html)

<a id="topic-2.2.2.2-2"></a>

###### Evaluation for long-term prophylaxis: guideline recommendation

> “We recommend that all patients with HAE are evaluated for LTP at every visit, with a shared decision-making approach.”
> “Successful LTP implies full disease control with minimal treatment burden and requires patient adherence, so that a shared decision-making approach is essential.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.2-3"></a>

###### First-line long-term prophylaxis agents: WAO guideline

> “We recommend SC pdC1-INH, lanadelumab, berotralstat, garadacimab, or donidalorsen as first-line options for LTP.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.2-4"></a>

###### Pediatric guideline: criteria and first-line agents by age

> “We recommend evaluating frequency and location of angioedema attacks, burden of disease, quality of life, patients' and caregivers' preferences, and availability of medications when considering long‐term prophylaxis.”
> “In children with hereditary angioedema due to C1 inhibitor deficiency aged between 6 and 12 years, we recommend the use of lanadelumab or plasma‐derived C1 inhibitor as first‐line long‐term prophylaxis.”
> “In adolescents with hereditary angioedema due to C1 inhibitor deficiency aged 12 years or older, we recommend the use of any of the following treatments: berotralstat or garadacimab or lanadelumab or plasma‐derived C1 inhibitor, as first‐line long‐term prophylaxis.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="topic-2.2.2.2-5"></a>

###### Criteria for starting long-term prophylaxis: health technology assessment

> “There are currently no consensus criteria on when to consider starting long-term prophylaxis for patients with HAE 1/2.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-2.2.2.2-6"></a>

###### Onvuzosiran in guideline and review discussion of investigational agents

> “ADX-324, a small-interfering RNA, is currently being investigated for HAE and looks promising to be an every 6 month subcutaneously injected medication.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “ADX-324 is a short interfering RNA (siRNA) in development for long-term prophylaxis in HAE type I/II.”

Source: [Uminski et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12618362/)

<a id="topic-2.2.2.2-7"></a>

###### Sponsor-stated intended use and dosing intervals

> “We are developing onvuzosiran as a Q6M and Q3M SC treatment for the prevention of HAE attacks.”
> “Onvuzosiran is delivered via SC administration, with target dosing intervals of Q6M and Q3M being studied in our ongoing, Phase 3 STOP-HAE clinical trial.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

> “for onvuzosiran, an investigational small interfering RNA (siRNA) therapeutic candidate, for prophylaxis to prevent attacks of hereditary angioedema (HAE).”

Source: [ADARx Pharmaceuticals Fast Track designation announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-receives-fda-fast-track-designation-for-onvuzosiran-for-the-treatment-of-hae/)

<a id="topic-2.2.2.2-8"></a>

###### Sponsor-stated rationale relative to current prophylaxis

> “Therefore, prophylaxis is the preferred approach for most patients.”
> “Taken together, there is remaining unmet medical need in HAE for a potent and long duration of action preventative therapy to provide patients with maximal attack suppression with lower burden of treatment, improved treatment compliance and enhanced quality of life.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.2.2.2-9"></a>

###### Phase 3 trial population: discontinuation of prior prophylaxis

> “It is administered every 3 or 6 months, potentially helping to make managing HAE simpler by requiring fewer doses compared to current treatments.”
> “Be willing to stop any long-term, preventative medication used to prevent attacks”
> “Have access to at least one acute therapy that has worked for you before”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="topic-2.2.2.2-10"></a>

###### Pipeline: navenibart, long-acting plasma kallikrein inhibitor

> “The company is studying navenibart, an investigational, long-acting plasma kallikrein inhibitor, in ALPHA-ORBIT, the ongoing and fully enrolled pivotal study in hereditary angioedema with every three-month and every six-month subcutaneous dosing, and ORBIT-EXPANSE, the long-term extension study.”
> “The program remains on track to report top-line results at six- and twelve-month endpoints in Q3 2027.”

Source: [BioCryst Pharmaceuticals (2026)](https://www.sec.gov/Archives/edgar/data/882796/000117184326007097/exh_991.htm)

> “Navenibart, a human monoclonal antibody targeting plasma kallikrein and engineered with Fc region modifications that extend its half-life to approximately 100 days, has advanced into phase 3 clinical trials.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.2-11"></a>

###### Pipeline: deucrictibant, oral bradykinin B2 receptor antagonist

> “Treatment with deucrictibant XR in participants with all types of HAE reduced the mean monthly attack rate by 83% (p<0.0001)”
> “Preparation of NDA dossier of deucrictibant XR for prophylaxis of AE-BK attacks ongoing; timeline remains on-track for submission in 1H2027”

Source: [Pharvaris (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.2.2.2-12"></a>

###### Pipeline: lonvoguran ziclumeran, in vivo gene editing

> “today announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lonvo-z and granted the BLA Priority Review with a PDUFA target action date of March 10, 2027.”

Source: [Intellia Therapeutics (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fda-acceptance-biologics-license)

> “The goal of this therapy is to provide lifelong control of HAE attacks with just a single dose.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.2-13"></a>

###### Pipeline: BW-20805, prekallikrein-directed siRNA

> “BW-20805 is an investigational siRNA therapeutic designed to silence plasma prekallikrein (PKK) messenger RNA, targeting a clinically validated pathway in HAE.”
> “As of the June 2026 data cut-off, 25 participants were randomized and dosed across three treatment groups: BW-20805: 600 mg every 24 weeks (Q24W), 300 mg Q24W, and 300 mg every 12 weeks (Q12W).”
> “Mean time-normalized monthly attack rates decreased by 83% in the 600 mg Q24W group, 96% in the 300 mg Q24W group, and 93% in the 300 mg Q12W group”

Source: [Argo Biopharma (2026)](https://www.prnewswire.com/news-releases/argo-biopharma-to-present-positive-phase-ii-updated-results-of-sirna-therapeutic-bw-20805-for-hae-at-bradykinin-symposium-2026-302869556.html)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

No evidence found.

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### US HAEA Medical Advisory Board guidelines: on-demand medication access

> “Effective treatment of HAE requires that all patients have rapid access to effective on-demand medications.”

Source: [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)

<a id="topic-2.2.2.4-2"></a>

###### On-demand treatment during long-term prophylaxis: guideline recommendations

> “We recommend that patients have access to ODT, even while receiving LTP.”
> “We recommend that patients or their caregivers are advised to always carry enough medication to treat at least 2 HAE attacks.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “We recommend supplying all pediatric patients with hereditary angioedema with acute treatment for at least two angioedema attacks even if they are on long‐term prophylaxis.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="topic-2.2.2.4-3"></a>

###### Self-administration and home therapy

> “Self-administration and home therapy are available for all C1-INH products, icatibant, berotralstat, sebetralstat, donidalorsen, garadacimab, and lanadelumab.”
> “We recommend that patients and their caregivers be educated in how to administer ODT, including self-administration with all available formulations.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.4-4"></a>

###### Monitoring of disease control with validated instruments

> “We recommend that all patients with HAE use validated instruments to assess disease activity, severity, disease control, treatment efficacy, and QoL, and that they undergo regular reassessments to ensure optimal therapeutic management.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “We recommend evaluating efficacy and safety of the long‐term prophylactic agent in pediatric patients with hereditary angioedema due to C1 inhibitor deficiency at least three and six months after initiation, then at least annually.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="topic-2.2.2.4-5"></a>

###### Specialist care and referral centers

> “We recommend that HAE patients be managed by physicians with expertise in the condition, with the support of a referral center.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Sponsor target product profile

> “Our target profile for onvuzosiran is to reach greater than 90% reduction in monthly attacks, with greater than 75% of patients achieving attack-free status, on Q3M or Q6M dosing schedule.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.2.2.7-2"></a>

###### Phase 2a: attack-free intervals in three participants, August 2026 cutoff

> “Despite dosing at levels below those utilized in our ongoing Phase 3 STOP-HAE clinical trial, all participants in the Phase 2a cohort remained attack-free for 3 months following the initial dose, with one patient remaining attack-free for 18 consecutive months on Q6M dosing as of the August 19, 2026 data cutoff date, after one mild attack on Day 153.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.2.2.7-3"></a>

###### Phase 2a: attack-free intervals in three participants, November 2026 cutoff

> “All three patients (3/3) were attack-free for 3 months after the initial dose”
> “Patient 202 (245mg, Q6M) remained attack-free for a consecutive 21 months after one mild attack at Day 153”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

<a id="topic-2.2.2.7-4"></a>

###### Prekallikrein suppression threshold associated with absence of attacks

> “We also correlated the episodes of attack with the PKK levels and found that no attacks occurred when the PKK suppression was >80%, suggesting that >80% suppression is potentially needed to achieve a maximal attack-free state.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

> “Notably, patients who had plasma kallikrein reduction of >80% were attack-free, supporting 300 mg Q6M dosing.”

Source: [Riedl et al. (2026b)](https://www.annallergy.org/article/S1081-1206%2826%2900563-6/fulltext)

> “The patients’ data also supports that PKK-KK response can be used to predict HAE attacks and PKK-KK reductions > 70% are likely to prevent HAE attacks.”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="topic-2.2.2.7-5"></a>

###### Timing of phase 3 efficacy results

> “Onvuzosiran (PKK): Phase 3 STOP-HAE topline data by year-end 2027”

Source: [ADARx Pharmaceuticals third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458321/adrx-ex99_1.htm)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
